Keywords: کاناککنمب; canakinumab; cardiovascular risk; CKD; inflammation;
مقالات ISI کاناککنمب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کاناککنمب; Familial Mediterranean fever; Pyrin; MEFV; Colchicine; Inadequate response; Colchicine resistant; Interleukin 1; Anakinra; Rilonacept; Canakinumab;
Keywords: کاناککنمب; OA; osteoarthritis; IL; interleukin-1β; TNF; tumor necrosis factor-α; MMPs; metalloproteinases; NO; nitric oxide; FDA; Drug Administration; EMEA; European Medicines Agency; PG; proteoglycans; iNOS; inducible nitric oxide synthase; TEM; transmission elec
Keywords: کاناککنمب; canakinumab; high-sensitivity C-reactive protein; interleukin-1β; pharmacodynamics; pharmacokinetics; type 2 diabetes mellitus;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobuli
Keywords: کاناککنمب; Anakinra; Brodalumab; Canakinumab; Eculizumab; Infection; Ixekizumab; Prevention; Rilonacept; Secukinumab; Tocilizumab;
Efficacy and safety of canakinumab in Schnitzler syndrome: AÂ multicenter randomized placebo-controlled study
Keywords: کاناککنمب; Autoinflammatory; canakinumab; IL-1; Schnitzler syndrome; urticaria; CAPS; Cryopyrin-associated periodic syndrome; CRP; C-reactive protein; DLQI; Dermatology Life Quality Index; IL-1Ra; IL-1 receptor antagonist; PGA; Physician global assessment; SAA; Seru
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease
Keywords: کاناککنمب; Behçet's disease; Interleukin-1; Anakinra; Canakinumab; Gevokizumab; Tuberculosis
Leczenie biologiczne we wtórnych zespoÅach hemofagocytarnych. PrzeglÄ
d piÅmiennictwa i opis przypadku zespoÅu aktywacji makrofagów w przebiegu leczenia etanerceptem ukÅadowej postaci mÅodzieÅczego idiopatycznego zapalenia stawów
Keywords: کاناککنمب; zespóÅ hemofagocytarny; zespóÅ aktywacji makrofagów; etanercept; infliximab; tocilizumab; canakinumab; rituximab; mÅodzieÅcze idiopatyczne zapalenie stawów; Hemophagocytic Lymphohistiocytosis; mMacrophage Activation syndrome; Etanercept; Inflixima
Canakinumab in Schnitzler Syndrome
Keywords: کاناککنمب; Schnitzler syndrome; interleukin-1; canakinumab; autoinflammatory
Efficacy and Safety of Biologic Treatments in Familial Mediterranean Fever
Keywords: کاناککنمب; Familial Mediterranean Fever; Infliximab; Etanercept; Adalimumab; Anakinra; Canakinumab;
Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial
Keywords: کاناککنمب; Canakinumab; Diabetes mellitus; Interleukin-1β; Metformin; Monoclonal antibodyCanakinumab; Diabète sucré; Interleukine-1β; Metformine; Anticorps monoclonal
Targeting the Unstable Plaque in Acute Coronary Syndromes
Keywords: کاناککنمب; acute coronary syndromes; atherosclerosis; canakinumab; colchicines; darapladib; methotrexate; plaque instability
Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes: What did we learn?
Keywords: کاناککنمب; Cryopyrin‐associated periodic disorders; Treatment; Anakinra; Rilonacept; Canakinumab
The Use of Canakinumab, a Novel IL-1β Long-Acting Inhibitor, in Refractory Adult-Onset Still's Disease
Keywords: کاناککنمب; adult-onset Still's disease; anakinra; canakinumab
Biological treatment in adult-onset Still's disease
Keywords: کاناککنمب; Adult-onset Still's disease; Biological agents; Anti-IL-1; Anti-IL-6; Anti-TNF-α; Canakinumab
Canakinumab, un anticuerpo monoclonal frente a IL-1β, con utilidad potencial en distintos procesos inflamatoriosCanakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes
Keywords: کاناککنمب; Canakinumab; SÃndromes periódicos asociados; a criopirinas; CAPS; IL-1; Canakinumab; Cryopyrin-associated periodic syndromes; CAPS; IL-1;
EditroialTratamiento de los sÃndromes periódicos asociados a la criopirina (CAPS)CAPS treatment
Keywords: کاناککنمب; SÃndromes periódicos asociados a criopirina; CIAS1; SÃndrome de Muckle-Wells; SÃndrome CINCA-NOMID; SÃndrome autoinflamatorio familiar inducido por el frÃo; Canakinumab; Anakinra; Rilonacept; Cryopyrin-associated periodic syndromes; CIAS1; Muckle-We
Physiopathologie et traitement de l’inflammation goutteuse
Keywords: کاناککنمب; Goutte; Microcristaux; Inflammation; Tophus; Mastocyte; Monocyte-macrophage; Polynucléaire neutrophile; Interleukine-1; Tgf-β; Auto-limitation; Colchicine; Glucocorticoïdes; Canakinumab; Anakinra; Rilonacept; Anti-inflammatoire non stéroïdien
Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature
Keywords: کاناککنمب; familial Mediterranean fever; interleukin-1; anakinra; canakinumab; inflammasome
Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome
Keywords: کاناککنمب; IL-1β; Anakinra; Canakinumab; Rilonacept; Autoinflammatory syndromes